SUMMARY Serum creatine kinase BB-isoenzyme (CK-BB) activity was studied on the first day of life in 31 acutely asphyxiated infants, 70 infants born after high risk pregnancies (pre-eclampsia or intrauterine growth retardation, or both), and 47 very low birthweight infants. Neurodevelopmental evaluation was carried out at 2-2-2-5 years. Eight infants died with, and eight without, hypoxic-ischaemic lesions of the brain, 14 had cerebral palsy, 16 had mild motor impairment, six had developmental delay without motor impairment, and 96 were normal at follow up. Infants who died with brain injury had significantly higher CK-BB activity than infants with normal outcomes (geometric mean 12 U/l); the mean difference was 82 U/l with a 95% confidence interval from 31 to 219 U/l. CK-BB in infants with cerebral palsy and mild motor impairment (geometric means 12 and 15 U/l, respectively) were similar to controls. CK-BB activity after birth is predictive of neonatal death but not of neurological damage in survivors.
Perinatal asphyxia is a common cause of neonatal mortality, and survivors are at risk of permanent brain damage, mainly cerebral palsy. In a population based study the incidence of cerebral palsy of perinatal origin was 1-1/1000 live births'; 47% of the handicapped infants had been born at full term. In low birthweight infants the incidence of brain injury was inversely correlated with gestational age with an overall incidence of 6-8% in survivors. 2 The classical indicators of asphyxia (the Apgar score and cord pH) are poor predictors of brain damage,34 so to detect a risk of hypoxic-ischaemic brain injury in the neonatal period more specific measurements are needed.
The BB-isoenzyme of creatine kinase (CK-BB) has been considered comparatively specific for brain tissue, and increased activity in serum5 or cerebrospinal fluid6 has been associated with brain damage in adults. Increased activity of CK-BB in serum has been reported in preterm infants with intraventricular haemorrhage, and in asphyxiated infants born at full term.8 9 Correlation between CK-BB activity and the neurological results of perinatal asphyxia has been reported, but the damaged survivors have been few. 'a 11 The aim of this follow up study was to find out if serum CK-BB activity on the first day of life is an indicator of perinatal brain damage.
Patients and methods
The infants studied were infants (fig 2) ; neither did the infants who died without hypoxic-ischaemic brain lesions (30 U/l) or those who had developmental delay without motor impairment.
In the very low birthweight group, no correlation was found between CK-BB activity, Apgar scores, or gestational age. The enzyme activities were similar in infants with all grades of intraventricular haemorrhage and in infants without. No correlation was found between CK-BB activity and the developmental quotient. The geometric means in infants with normal outcome, mild motor impairment, and cerebral palsy were 14, 29, and 20 U/l, respectively (fig 3) . The two infants who died with brain damage had high values. The range of CK-BB activity in the four infants who died without brain injury was 7-31 U/l. CK-BB activities were similar in infants treated with phenobarbitone, which wasgiven in most cases as part of a prophylactic trial,'4 and in those not receiving the drug (geometric means 16 and 13 U/l, respectively). When all three study groups were combined, infants who died with brain damage had significantly higher CK-BB activities than those with normal outcome (12 U/l), the mean difference was 82 U/l (95% confidence interval 31 to 219 U/I (p<0-001). The infants with mild motor impairment or cerebral palsy (geometric mean 15 and 12 U/l, respectively), however, did not differ from the normal ones.
Discussion
The method for determining CK-BB activity used in the present study has a sensitivity of 2 U/l, which is sufficient for the present purpose as CK-BB activity in healthy newborn infants is higher than in adults. 7 CK-BB activity in cord blood is about twice that in maternal blood,9 and increases after birth with a peak at the age of about 5-10 hours.'0 11 17 The mode of delivery does not affect the CK-BB activity in cord blood or later during the first day. '7 18 Although the main source of serum CK-BB in Prognostic value of creatine kinase BB-isoenzyme in high risk newborn infants 567 man is the brain, this isoenzyme is found in many tissues-for example, gastrointestinal tract, kidney, lung, liver, uterus, and placenta.19 The vessel walls of both umbilical artery and vein have high CK-BB activities, even higher than placenta.20 Thus cord blood CK-BB activity may be partly derived from uterine, placental, or umbilical tissues and cannot be considered specific for the fetal brain. Increasing activity in blood after birth, however, must be released from tissues in the newborn infant, and probably mainly the brain. This is suggested by the finding that infants with necrotising enterocolitis, or lung or kidney disease, do not have higher activities than control infants, whereas infants with severe asphyxia and neurological damage do.9 In the present study the age at blood sampling (10 hours on average) was chosen on the basis of previous studies10 17 close to the supposed peak activity.
In newborn infants who died of severe brain damage, serum CK-BB on day 1-4 was significantly increased.8 By repeated serum CK-BB measurements, the outcome at a mean age of 7 months was predictable in 77% of 22 severely asphyxiated term infants.10 In another study of 33 asphyxiated infants born at full term, adverse outcome could be predicted by CK-BB activity at the age of 4 hours." Adverse outcome in both these studies, however, was usually death, as only three in the first and four in the second study survived with neurological abnormalities.
In the present study, severe brain damage leading to death in the neonatal period was associated with high CK-BB activities, especially after high risk pregnancy. Cerebral palsy or mild motor impairment, however, could not be predicted.
Brain injury in the young infant is not necessarily associated with the process of birth. Although most infants in the high risk pregnancy group had intrapartum asphyxia, the insult might have occurred earlier. In the other two groups damage during labour or at birth seems probable.
In cases with fatal intracerebral haemorrhage, CK-BB activity was high, whereas infants with grades I-III intraventricular haemorrhage had activities similar to those without bleeding. Significantly higher CK-BB activities on the first day have previously been found in infants with haemorrhage,7 but the extent of the bleeding was more severe than in the present study.
It is likely that the release of CK-BB from damaged neurones and through the blood brain barrier is dependent on the severity of the insult. Enzyme activities in the cerebrospinal fluid of newborn infants could be a better predictor of brain damage than those in serum, as is the case in adults. 7 The aim of this study, however, was to look for a simple serum assay with the potential for screening infants at risk for brain damage, for which purpose a lumbar puncture would not be suitable. Unfortunately, serum CK-BB activity does not seem to be accurate enough.
In conclusion, a single measurement of CK-BB activity on the first day of life cannot be used as a prognostic indicator of long term neurological outcome, but high activities in critically ill newborn infants indicate a risk of neonatal death. 
